Clinical activity of everolimus in relapsed/refractory marginal zone B-cell lymphomas

Results of a phase II study of the International Extranodal Lymphoma Study Group

Annarita Conconi, Markus Raderer, Silvia Franceschetti, Liliana Devizzi, Andrés J M Ferreri, Massimo Magagnoli, Luca Arcaini, Pier Luigi Zinzani, Giovanni Martinelli, Umberto Vitolo, Barbara Kiesewetter, Elena Porro, Anastasios Stathis, Gianluca Gaidano, Franco Cavalli, Emanuele Zucca

Research output: Contribution to journalArticle

25 Citations (Scopus)

Abstract

The International Extranodal Lymphoma Study Group coordinated a phase II trial to evaluate the activity and safety of everolimus in marginal zone lymphomas (MZLs). Thirty patients with relapsed/refractory MZLs received everolimus for six cycles or until dose-limiting toxicity or progression. Median age was 71 years (range, 51-88 years). Twenty patients had extranodal, six splenic, four nodal MZL. Twenty-four patients had stage III-IV. Median number of prior therapies was two (range 1-5). Seventeen patients had early treatment discontinuation, in most cases due to toxicity. Median number of cycles was 4·5 (range, 1-16). Among the 24 assessable patients, the overall response rate (ORR) was 25% (95% confidence interval: 10-47). Grade 3-4 adverse events were neutropenia and thrombocytopenia (17% of patients, each), infections (17%), mucositis and odontogenic infections (13%) and lung toxicity (3%). The median response duration was 6·8 months (range, 1·4-11·1+). After a median follow-up of 14·5 months, five deaths were reported: four deaths were due to lymphoma, one was due to toxicity. In an intent-to-treat analysis, the projected median progression-free survival was 14 months. The moderate antitumour activity of everolimus in relapsed/refractory MZLs and the observed toxicity limit its therapeutical applicability in these indolent entities. Lower doses of the drug and, perhaps, different strategies including combination with additional agents need to be explored.

Original languageEnglish
Pages (from-to)69-76
Number of pages8
JournalBritish Journal of Haematology
Volume166
Issue number1
DOIs
Publication statusPublished - 2014

Fingerprint

Marginal Zone B-Cell Lymphoma
Lymphoma
Mucositis
Infection
Neutropenia
Thrombocytopenia
Disease-Free Survival
Everolimus
Confidence Intervals
Safety
Lung
Therapeutics
Pharmaceutical Preparations

Keywords

  • Everolimus
  • Mammalian target of rapamycin
  • Marginal zone B-cell lymphoma
  • Mucosa-associated lymphoid tissue lymphoma
  • Non-Hodgkin lymphoma

ASJC Scopus subject areas

  • Hematology

Cite this

Clinical activity of everolimus in relapsed/refractory marginal zone B-cell lymphomas : Results of a phase II study of the International Extranodal Lymphoma Study Group. / Conconi, Annarita; Raderer, Markus; Franceschetti, Silvia; Devizzi, Liliana; Ferreri, Andrés J M; Magagnoli, Massimo; Arcaini, Luca; Zinzani, Pier Luigi; Martinelli, Giovanni; Vitolo, Umberto; Kiesewetter, Barbara; Porro, Elena; Stathis, Anastasios; Gaidano, Gianluca; Cavalli, Franco; Zucca, Emanuele.

In: British Journal of Haematology, Vol. 166, No. 1, 2014, p. 69-76.

Research output: Contribution to journalArticle

Conconi, A, Raderer, M, Franceschetti, S, Devizzi, L, Ferreri, AJM, Magagnoli, M, Arcaini, L, Zinzani, PL, Martinelli, G, Vitolo, U, Kiesewetter, B, Porro, E, Stathis, A, Gaidano, G, Cavalli, F & Zucca, E 2014, 'Clinical activity of everolimus in relapsed/refractory marginal zone B-cell lymphomas: Results of a phase II study of the International Extranodal Lymphoma Study Group', British Journal of Haematology, vol. 166, no. 1, pp. 69-76. https://doi.org/10.1111/bjh.12845
Conconi, Annarita ; Raderer, Markus ; Franceschetti, Silvia ; Devizzi, Liliana ; Ferreri, Andrés J M ; Magagnoli, Massimo ; Arcaini, Luca ; Zinzani, Pier Luigi ; Martinelli, Giovanni ; Vitolo, Umberto ; Kiesewetter, Barbara ; Porro, Elena ; Stathis, Anastasios ; Gaidano, Gianluca ; Cavalli, Franco ; Zucca, Emanuele. / Clinical activity of everolimus in relapsed/refractory marginal zone B-cell lymphomas : Results of a phase II study of the International Extranodal Lymphoma Study Group. In: British Journal of Haematology. 2014 ; Vol. 166, No. 1. pp. 69-76.
@article{7cc22ec4d540421dbc01cacef0d07b9e,
title = "Clinical activity of everolimus in relapsed/refractory marginal zone B-cell lymphomas: Results of a phase II study of the International Extranodal Lymphoma Study Group",
abstract = "The International Extranodal Lymphoma Study Group coordinated a phase II trial to evaluate the activity and safety of everolimus in marginal zone lymphomas (MZLs). Thirty patients with relapsed/refractory MZLs received everolimus for six cycles or until dose-limiting toxicity or progression. Median age was 71 years (range, 51-88 years). Twenty patients had extranodal, six splenic, four nodal MZL. Twenty-four patients had stage III-IV. Median number of prior therapies was two (range 1-5). Seventeen patients had early treatment discontinuation, in most cases due to toxicity. Median number of cycles was 4·5 (range, 1-16). Among the 24 assessable patients, the overall response rate (ORR) was 25{\%} (95{\%} confidence interval: 10-47). Grade 3-4 adverse events were neutropenia and thrombocytopenia (17{\%} of patients, each), infections (17{\%}), mucositis and odontogenic infections (13{\%}) and lung toxicity (3{\%}). The median response duration was 6·8 months (range, 1·4-11·1+). After a median follow-up of 14·5 months, five deaths were reported: four deaths were due to lymphoma, one was due to toxicity. In an intent-to-treat analysis, the projected median progression-free survival was 14 months. The moderate antitumour activity of everolimus in relapsed/refractory MZLs and the observed toxicity limit its therapeutical applicability in these indolent entities. Lower doses of the drug and, perhaps, different strategies including combination with additional agents need to be explored.",
keywords = "Everolimus, Mammalian target of rapamycin, Marginal zone B-cell lymphoma, Mucosa-associated lymphoid tissue lymphoma, Non-Hodgkin lymphoma",
author = "Annarita Conconi and Markus Raderer and Silvia Franceschetti and Liliana Devizzi and Ferreri, {Andr{\'e}s J M} and Massimo Magagnoli and Luca Arcaini and Zinzani, {Pier Luigi} and Giovanni Martinelli and Umberto Vitolo and Barbara Kiesewetter and Elena Porro and Anastasios Stathis and Gianluca Gaidano and Franco Cavalli and Emanuele Zucca",
year = "2014",
doi = "10.1111/bjh.12845",
language = "English",
volume = "166",
pages = "69--76",
journal = "British Journal of Haematology",
issn = "0007-1048",
publisher = "John Wiley & Sons, Ltd (10.1111)",
number = "1",

}

TY - JOUR

T1 - Clinical activity of everolimus in relapsed/refractory marginal zone B-cell lymphomas

T2 - Results of a phase II study of the International Extranodal Lymphoma Study Group

AU - Conconi, Annarita

AU - Raderer, Markus

AU - Franceschetti, Silvia

AU - Devizzi, Liliana

AU - Ferreri, Andrés J M

AU - Magagnoli, Massimo

AU - Arcaini, Luca

AU - Zinzani, Pier Luigi

AU - Martinelli, Giovanni

AU - Vitolo, Umberto

AU - Kiesewetter, Barbara

AU - Porro, Elena

AU - Stathis, Anastasios

AU - Gaidano, Gianluca

AU - Cavalli, Franco

AU - Zucca, Emanuele

PY - 2014

Y1 - 2014

N2 - The International Extranodal Lymphoma Study Group coordinated a phase II trial to evaluate the activity and safety of everolimus in marginal zone lymphomas (MZLs). Thirty patients with relapsed/refractory MZLs received everolimus for six cycles or until dose-limiting toxicity or progression. Median age was 71 years (range, 51-88 years). Twenty patients had extranodal, six splenic, four nodal MZL. Twenty-four patients had stage III-IV. Median number of prior therapies was two (range 1-5). Seventeen patients had early treatment discontinuation, in most cases due to toxicity. Median number of cycles was 4·5 (range, 1-16). Among the 24 assessable patients, the overall response rate (ORR) was 25% (95% confidence interval: 10-47). Grade 3-4 adverse events were neutropenia and thrombocytopenia (17% of patients, each), infections (17%), mucositis and odontogenic infections (13%) and lung toxicity (3%). The median response duration was 6·8 months (range, 1·4-11·1+). After a median follow-up of 14·5 months, five deaths were reported: four deaths were due to lymphoma, one was due to toxicity. In an intent-to-treat analysis, the projected median progression-free survival was 14 months. The moderate antitumour activity of everolimus in relapsed/refractory MZLs and the observed toxicity limit its therapeutical applicability in these indolent entities. Lower doses of the drug and, perhaps, different strategies including combination with additional agents need to be explored.

AB - The International Extranodal Lymphoma Study Group coordinated a phase II trial to evaluate the activity and safety of everolimus in marginal zone lymphomas (MZLs). Thirty patients with relapsed/refractory MZLs received everolimus for six cycles or until dose-limiting toxicity or progression. Median age was 71 years (range, 51-88 years). Twenty patients had extranodal, six splenic, four nodal MZL. Twenty-four patients had stage III-IV. Median number of prior therapies was two (range 1-5). Seventeen patients had early treatment discontinuation, in most cases due to toxicity. Median number of cycles was 4·5 (range, 1-16). Among the 24 assessable patients, the overall response rate (ORR) was 25% (95% confidence interval: 10-47). Grade 3-4 adverse events were neutropenia and thrombocytopenia (17% of patients, each), infections (17%), mucositis and odontogenic infections (13%) and lung toxicity (3%). The median response duration was 6·8 months (range, 1·4-11·1+). After a median follow-up of 14·5 months, five deaths were reported: four deaths were due to lymphoma, one was due to toxicity. In an intent-to-treat analysis, the projected median progression-free survival was 14 months. The moderate antitumour activity of everolimus in relapsed/refractory MZLs and the observed toxicity limit its therapeutical applicability in these indolent entities. Lower doses of the drug and, perhaps, different strategies including combination with additional agents need to be explored.

KW - Everolimus

KW - Mammalian target of rapamycin

KW - Marginal zone B-cell lymphoma

KW - Mucosa-associated lymphoid tissue lymphoma

KW - Non-Hodgkin lymphoma

UR - http://www.scopus.com/inward/record.url?scp=84902357461&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84902357461&partnerID=8YFLogxK

U2 - 10.1111/bjh.12845

DO - 10.1111/bjh.12845

M3 - Article

VL - 166

SP - 69

EP - 76

JO - British Journal of Haematology

JF - British Journal of Haematology

SN - 0007-1048

IS - 1

ER -